Nanobiotix is trading 5.99% down at $29.49 in pre-market, with the reason for the decline unclear.
- No clear company-specific announcement explaining the November 2 move was identified; the latest prominent update was October 24 clinical data for its melanoma study.
- The supplied broader-market context points to a pre-market rebound, which does not clearly explain the decline.
- Friday’s weakness also came without a clear company-specific catalyst.